Histone deacetylase 6 and programmed death ligand-1 expressions after neoadjuvant chemotherapy are upregulated in patients with ovarian high-grade serous carcinoma
Abstract Patients with ovarian high-grade serous carcinoma (OHGSC) gradually acquire resistance to standard chemotherapy following recurrence. In our previous study on OHGSC, histone deacetylase (HDAC) 6 upregulation led to a poor prognosis, and programmed death ligand-1 (PD-L1) expression was posit...
Saved in:
| Main Authors: | Mitsutake Yano, Tomomi Katoh, Mariko Miyazawa, Aiko Ogasawara, Kosei Hasegawa, Eiji Kobayashi, Masanori Yasuda |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-06-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-02329-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Design, synthesis, and biological evaluation of novel histone deacetylase 6 selective inhibitors
by: Tianyi Zhang, et al.
Published: (2022-05-01) -
Research advances of histone deacetylases in acute kidney injury
by: Deng Fang-jing, et al.
Published: (2022-04-01) -
Histone deacetylases repress the accumulation of licochalcone A by inhibiting the expression of flavonoid biosynthetic pathway-related genes in licorice (Glycyrrhiza inflata)
by: Jiangyi Zeng, et al.
Published: (2025-05-01) -
Unveiling the role of histone deacetylases in neurological diseases: focus on epilepsy
by: Dan-Feng Cao, et al.
Published: (2024-11-01) -
Design, Synthesis, and Preliminary Antiproliferative Evaluation of 1,2,4-Thiadiazole Derivatives as Possible Histone Deacetylase Inhibitors
by: Rusul Mohammed Hasan Ali, et al.
Published: (2025-02-01)